Accuray’s CyberKnife System treatment featured in two prostate cancer studies

Accuray announced that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife System in the treatment of high-risk and recurrent prostate cancer. The CyberKnife System enables treatment of prostate cancer using a form of radiation therapy called stereotactic body radiation therapy – SBRT -in which precise, high doses of radiation are delivered over a shorter duration than traditional treatments. Study authors concluded, “At the 3-year follow-up mark, favorable biochemical control was achieved, and patients had largely recovered to near baseline urinary and bowel function…These findings underscore the potential of SBRT as a convenient treatment option for high-risk prostate cancer, offering promising outcomes and preserving patient quality of life.” Provide a viable option with “a low incidence of short-term genitourinary and gastrointestinal toxicities” for reirradiation of locally recurrent prostate cancer.